人福医药：屈螺酮炔雌醇片获得药品注册证书

Core Viewpoint - The approval of the drug "Drospirenone and Ethinyl Estradiol Tablets" by the National Medical Products Administration marks a significant milestone for the company, allowing it to sell this product in the domestic market, which will positively impact its product line and overall business performance [1]. Group 1 - The company’s subsidiary, Wuhan Jiulong Renfu Pharmaceutical Co., Ltd., has received the drug registration certificate for Drospirenone and Ethinyl Estradiol Tablets [1]. - The approval indicates that the company is now qualified to market this drug in China, enhancing its product offerings [1]. - The company plans to arrange for the production and market launch of the drug based on market demand [1].